Displaying drugs 126 - 150 of 7273 in total
Pregabalin
Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects...
Approved
Investigational
Nedocromil
A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Approved
Investigational
Cenobamate
Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels. Cenobamate was granted FDA approval on 21 November 2019.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 CYP2A6 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP2C8 Inducers …
Tezacaftor
Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was approved by the FDA on February 12, 2018. Cystic Fibrosis is an autosomal recessive disorder caused...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inhibitors …
Omaveloxolone
Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties.[A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress. In patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 pathway is impaired, and Nrf2 activity...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C8 Inducers ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 CYP2C8 Substrates …
Clobazam
Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others. . Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike older 1,4-benzodiazepines, clobazam has...
Approved
Illicit
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP2B6 Substrates …
Vardenafil
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the...
Approved
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors …
Zafirlukast
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C8 Substrates …
Idelalisib
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab...
Approved
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers …
Dabrafenib
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C19 Inducers …
Iothalamic acid
Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent.
Approved
Methylprednisone
Methylprednisone has been used in trials studying the treatment of Leukemia, Rheumatoid Arthritis, Renal Transplantation, Kidney Transplantation, and Acute Lymphocytic Leukemia, among others.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Tirbanibulin
Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. Actinic keratosis is a chronic condition characterized...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors …
Osilodrostat
Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2B6 Substrates ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors …
Mitapivat
Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. Defects in the pyruvate kinase enzyme in various red blood cells disorders lead to the lack of energy production for red...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates …
Testosterone undecanoate
Testosterone undecanoate is the ester prodrug of testosterone and has a mid-chain fatty acid at the carbon 17β position. It was developed via fatty acid esterification of testosterone in order to achieve orally administer testosterone. There are oral and intramuscular formulations available for testosterone undecanoate: both formulations are indicated for...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP2B6 Substrates ... Cytochrome P-450 CYP2C8 Substrates …
Ethambutol
Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis. Ethambutol was granted FDA...
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Terbinafine
Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell...
Approved
Investigational
Vet approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A4 Inducers …
Colchicine
Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events....
Approved
Matched Categories: … P-glycoprotein inducers ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2E1 Inducers …
Oritavancin
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Sitaxentan
Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity.
Approved
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C9 Substrates …
Betamethasone phosphate
Betamethasone phosphate is a prodrug that is rapidly hydrolyzed, providing rapidly accessible betamethasone to agonize glucocorticoid receptors. Betamethasone provides greater anti-inflammatory activity than prednisolone with less sodium and water retention. Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.
Approved
Vet approved
Matched Categories: … P-glycoprotein inducers ... Cytochrome P-450 CYP3A Inducers ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A4 Inducers …
Levetiracetam
Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918]...
Approved
Matched Categories: … P-glycoprotein substrates …
Matched Products: … KEPPRA 100MG/ML 10ML DOS P ... KEPPRA 100MG/ML 3ML M DO P ... KEPPRA 100MG/ML M 1ML DO P …
Matched Products: … KEPPRA 100MG/ML 10ML DOS P ... KEPPRA 100MG/ML 3ML M DO P ... KEPPRA 100MG/ML M 1ML DO P …
Fexinidazole
Human African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by T. brucei gambiense and T. brucei rhodesiense, remains a moderate risk (>1/10,000 inhabitants per year in endemic areas) despite focussed control efforts. Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inducers ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP1A2 Substrates …
Progesterone
Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss . Progesterone is used in various contraceptive preparations to prevent ovulation...
Approved
Vet approved
Matched Categories: … P-glycoprotein inducers ... P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 CYP2A6 Inducers ... Cytochrome P-450 Substrates …
Displaying drugs 126 - 150 of 7273 in total